减低剂量的地西他滨治疗骨髓增生异常综合征患者1例并文献复习

A case of reduced-dose decitabine in the treatment of myelodysplastic syndrome and a review of the literature

骨髓增生异常综合征(MDS)又称为难治性贫血,依赖输血,高风险向急性白血病转化,严重影响患者的生活质量和生存周期。因此尽早经骨髓形态学、免疫学、细胞遗传学、分子生物学等检查明确诊断,精准预后分层及规范化治疗至关重要。本文通过回顾1例MDS(高危组)患者,应用不同剂量地西他滨治疗并复习相关文献,探讨减低剂量地西他滨治疗MDS患者效果与安全性。

Myelodysplastic syndrome(MDS),also known as refractory anemia,depends on blood transfusion and has a high risk of transformation to acute leukemia,which seriously affects the quality of life and survival cycle of patients.Therefore,it is very important to make a definite diagnosis as early as possible through bone marrow morphology,immunology,cytogenetics,molecular biology and other examinations,and to stratify precise prognosis and standardize treatment.In this paper,a case of MDS(high-risk group)was reviewed,and different doses of demitabine were applied in the treatment of MDS patients and relevant literature was reviewed to explore the efficacy and safety of reduced dose of demitabine in the treatment of MDS patients.